Lactobacillus acidophilus and inulin for memory and thinking problems in adults with obesity
Tests a probiotic and inulin supplement on thinking skills in adults with obesity.
Plain-language title generated from the registry record
Registry title: Lactobacillus Acidophilus and Inulin for Cognitive Impairment in Obesity
Key facts
- Where
- Huixquilucan, MexicoSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 40 years old?
Source: NCT07810517, who can take part
Where in Mexico
- Universidad AnahuacHuixquilucan, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anahuac University
- Trial code
- NCT07810517
- Record updated
- 10 September 2026
- Original description
This randomized crossover clinical trial aims to evaluate the effect of a synbiotic containing Lactobacillus acidophilus and inulin on cognitive function in adults with obesity and mild cognitive impairment. Forty participants aged 30-40 years will be randomly assigned to two groups. Participants will receive either the synbiotic intervention or a control preparation, followed by crossover to the alternate intervention. Cognitive function will be evaluated using the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and Memory Alteration Test (M@T). Fecal butyrate and Lactobacillus acidophilus, as well as serum inflammatory cytokines and BDNF, will also be assessed to explore potential mechanisms involving the gut-brain axis.Read full original descriptionShow less
Effect of Lactobacillus Acidophilus Combined With Inulin on Cognitive Impairment in Patients With Obesity
This randomized crossover clinical trial aims to evaluate the effect of a synbiotic containing Lactobacillus acidophilus and inulin on cognitive function in adults with obesity and mild cognitive impairment. Forty participants aged 30-40 years will be randomly assigned to two groups. Participants will receive either the synbiotic intervention or a control preparation, followed by crossover to the alternate intervention. Cognitive function will be evaluated using the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and Memory Alteration Test (M@T). Fecal butyrate and Lactobacillus acidophilus, as well as serum inflammatory cytokines and BDNF, will also be assessed to explore potential mechanisms involving the gut-brain axis.
Inclusion: Adults aged 30 to 40 years; Diagnosis of obesity for more than 10 years; Presence of mild cognitive impairment, evaluated using cognitive assessment scales; BMI ≥30 kg/m²; Body fat percentage ≥35% in women and ≥25% in men; Willingness to participate and provide written informed consent.
Exclusion: Antibiotic use during the 3 months prior to treatment; Advanced cognitive impairment; Diseases associated with cognitive impairment, including Alzheimer's disease, cerebral ischemia, cerebrovascular events, severe traumatic brain injury, or motor deficits; Allergy to almonds or any component of the synbiotic or vehicle; Diagnosed gastrointestinal disorders, including irritable bowel syndrome or inflammatory bowel disease, that could influence study outcomes; Diagnosis of type 2 diabetes mellitus; Consumption of probiotics or supplements and/or frequent intake of high-fiber or fermented foods.